SYDNEY, Australia, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced that it had contracted Italchimici SpA to market and distribute its asthma diagnostic and management tool, Aridol, in Italy. Pharmaxis is awaiting marketing authorisation for Aridol in Europe.
Dr Alan Robertson, Pharmaxis CEO said “The agreement with Italchimici provides us with direct access to an established and extensive network of asthma and allergy specialists in one of the largest markets in Europe. Italchimici, like other partners already announced for Scandinavia, Switzerland and Greece, was selected on the basis of their complementary range of respiratory products, excellent local knowledge and the dedicated resources they can commit to making Aridol a success.”
Bill Garrow, Italchimici Managing Director said: “Italchimici has a long and proud heritage in respiratory medicine and Aridol will be a perfect addition to our portfolio. We look forward to working with Pharmaxis and contributing to the overall success of Aridol in the Europe.”
Pharmaxis lodged its application for regulatory and marketing approval of Aridol with the Swedish Medical Products Agency (MPA) in May 2005, and anticipates registration for Aridol in 2006. Following Swedish registration, Pharmaxis will seek approval of Aridol in the 27 other European member states via the mutual recognition procedure.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .
About Italchimici SpA
Rome-based Italchimici SpA is a private Italian pharmaceutical company specializing in the manufacture and marketing of respiratory and gastrointestinal prescription medicines. Founded in the 1960s, later part of the Fisons Plc group, and re-privatised in 1996 following a management buyout, it has continued the specialisation in asthma and allergy which has characterised the company’s history.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this press release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the “Risk Factors and Other Uncertainties” section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
Contact: Alan Robertson Chief Executive Officer Tel: +61-2-9454-7200 Fax: +61-2-9451-3622 Released through: United States: Brandon Lewis Trout Group Tel: +1-212-477-9007 Email: blewis@troutgroup.com Australia: Ashley Rambukwella Financial & Corporate Relations Pty Ltd. Tel: +61-2-8264-1004 or +61-407-231-282 Email: a.rambukwella@fcr.com.au
Pharmaxis Ltd
CONTACT: Alan Robertson of Pharmaxis, +61-2-9454-7200 or fax,+61-2-9451-3622; or Brandon Lewis of Trout Group for Pharmaxis,+1-212-477-9007, or blewis@troutgroup.com; or Ashley Rambukwella ofFinancial & Corporate Relations Pty Ltd. for Pharmaxis, +61-2-8264-1004, or+61-407-231-282, or a.rambukwella@fcr.com.au
Web site: http://www.pharmaxis.com.au/
